With the move of the PROFID project coordinators, Prof. Gerhard Hindricks and Dr. Nikolaos Dagres, from Heart Center Leipzig to Deutsches Herzentrum der Charité (DHZC), Helios Health Institute and the third linked party Leipzig Heart Science terminated from the PROFID project and all tasks and responsibilities were transferred to Charité – Universitätsmedizin Berlin (CUB). Since January 1, 2024, CUB acts therefore as coordinator of the PROFID project and as sponsor of the PROFID EHRA clinical trial.

CUB is one of the largest university hospitals in Europe. All clinical care, research and teaching is delivered by physicians and researchers of the highest international standard. Having marked its 300-year anniversary in 2010, CUB proudly lays claim to more than half of all German Nobel Prize winners in Physiology or Medicine, e.g., Emil von Behring, Robert Koch, and Paul Ehrlich. CUB represents a medical faculty serving Humboldt Universtität zu Berlin and Freie Universität Berlin. It extends over 4 campuses, has more than 100 Departments and Institutes, making up a total of 17 Charité Centers with 21,556 staff including its subsidiaries, the annual revenue is €2.3 billion. CUB is internationally renowned for excellence in teaching and training.

At CUB, approximately 5,242 researchers are actively engaged in the development of pioneering innovations in the field of medicine. Committed to the highest standards of quality and sustainability, they work across 1,000 projects, working groups and collaborative projects. Currently, CUB is involved in more than 140 collaborative or individual Horizon 2020 or Horizon Europe projects.

With eight departments and institutes, and about 2,500 employees at three clinical campuses, Deutsches Herzzentrum der Charité (DHZC) is set to be one of the largest cardiovascular centers in Germany, treating a full range of cardiovascular diseases and conditions in patients of all ages. The DHZC is being established as a leading international cardiovascular center that will raise the bar for patient care, research and teaching, and infrastructure and logistics. The center offers bright prospects for development, especially in precision medicine and the use of artificial intelligence. Harnessing clinical research to drive advances in innovative therapies will underscore the translational approach.